For instance, an AZ‐modified BODIPY photosensitizer could combine the advantages of the antiangiogenesis therapy and PDT, which mitigated the effects of PDT‐based hypoxia (Figure 5c).[79] This prodrug showed a specific affinity to aggressive cancer cells (MDA‐MB‐231 cells) overexpressing CAIX derived from breast cancer patients.[80] This study provides an attractive therapeutic approach for targeting CAIX‐overexpressing tumors. This evidence concerns the gene CA9 and breast carcinoma.